Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Sogroya | somapacitan | Growth Hormone Deficiency (GHD) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Livmarli | maralixibat | Alagille syndrome | Active | |||
| Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Evkeeza | evinacumab | Homozygous familial hypercholesterolemia (HoFH) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation, 2 years and older | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cosentyx | secukinumab | Hidradenitis suppurativa | Suspended | |||
| Asparlas | calaspargase pegol | Acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Reimburse with clinical criteria and/or conditions | Active | ||
| Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | Crohns disease | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 29, 2024